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Abstract
The main lifestyle interventions to modify serum HDL cholesterol include
physical exercise, weight loss with either caloric restriction or specific dietary
approaches, and smoking cessation. Moderate alcohol consumption can be
permitted in some cases. However, as these interventions exert multiple effects,
it is often difficult to discern which is responsible for improvement in HDL
outcomes. It is particularly noteworthy that recent data questions the use of HDL
cholesterol as a risk factor and therapeutic target since randomised interventions
and Mendelian randomisation studies failed to provide evidence for such an
approach. Therefore, these current data should be considered when reading and
interpreting this review. Further studies are needed to document the effect of
lifestyle changes on HDL structure–function and health.
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Abbreviations
ABC Adenosine triphosphate-binding cassette transporter
Apo Apolipoprotein
CVD Cardiovascular disease
CETP Cholesteryl ester transfer protein
HL Hepatic lipase
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LCAT Lecithin–cholesterol acyltransferase
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LPL Lipoprotein lipase
Lp-PLA2 Lipoprotein-associated phospholipase A2
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PLTP Phospholipid transfer protein
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1 HDL and Diet
The landmark cross-cultural and migration studies of Ancel Keys in the 1950s were
the first to identify associations between serum HDL cholesterol (HDL-C) and diet
and lifestyle factors in free-living populations (Keys 1980a). These early studies
laid the foundation for the development of the diet–heart hypothesis, by revealing
links between the incidence of coronary heart disease, raised serum cholesterol and
energy derived from saturated fat. They also helped to establish diet as a determi-
nant of low HDL in obesity (Keys 1980b). It has been established that certain
dietary saturated fatty acids (SFA), with a chain length of between 12 and
16 carbons, and dietary cholesterol can increase both serum low-density lipoprotein
cholesterol (LDL-C) and, somewhat paradoxically with respect to cardiovascular
disease (CVD) risk, HDL-C (Grundy and Denke 1990). Conversely, the replace-
ment of SFA with either polyunsaturated (PUFA) or monounsaturated fatty acids
(MUFA) has been shown to reduce serum HDL-C. Moreover, the replacement of
dietary fat with carbohydrate has also been shown to produce significant reductions
in serum HDL-C (Katan et al. 1997; Stanhope et al. 2013). Heightened awareness of
the risk associated with dietary sugars in the early 1970s (Yudkin 1972) has
resurfaced recently, in part, through escalation of obesity-related cardiometabolic
risk and increased understanding of how extrinsic sugars influence HDL by
adversely affecting the metabolism of triacylglycerol (TAG) (Lustig 2010). The
history of diet and HDL has evolved in the era of the LDL-lowering statins, which
are relatively ineffective in raising HDL-C, and leave behind what is often
described as untreated ‘residual risk’ (Belsey et al. 2008). This situation has created
a need for alternative HDL-targeted drugs and also increased awareness of the
importance of diet as a modifier of HDL structure and function.
1.1 Effects of Substituting Dietary Saturated Fatty Acids
Serum HDL-C has been shown to be influenced by both the amount and quality of
dietary fatty acids and carbohydrate. In the past, the relative effects of dietary fatty
acids on HDL-C have been described in absolute terms, that is, SFA tends to raise
HDL-C, whilst PUFA, trans fatty acids and carbohydrate, all tend to reduce
HDL-C, with MUFA being relatively neutral (Grundy and Denke 1990). However,
in reality the absolute effect of fatty acids, or any macronutrient, on HDL-C cannot
be measured, as its addition or replacement may be counter-affected by whatever
fatty acid or carbohydrate takes its place to maintain a feasible diet. This phenome-
non of substitution limits the ability to interpret the impact of dietary
macronutrients on HDL and CVD risk to ‘relative’, rather than ‘absolute’ effects.
Meta-analyses of intervention studies have provided strong evidence to show that
the iso-energetic replacement of SFA with PUFA, MUFA and carbohydrate
decreases HDL-C, with carbohydrate exerting the greatest impact in lowering
both HDL-C and the total cholesterol–HDL-C ratio (Mensink et al. 2003). In
contrast, the iso-energetic replacement of carbohydrate with all dietary fatty
HDL and Lifestyle Interventions 571
acids, other than trans fatty acids, tends to raise HDL-C (Micha and Mozaffarian
2010). Estimates for the relative magnitude of change in the concentration of serum
HDL-C in response to these dietary substitutions are directly proportional to the
amount of energy being exchanged. An iso-energetic exchange of 5 % energy from
carbohydrate to SFA, MUFA and PUFA is associated with increases in HDL-C of
0.05, 0.04 and 0.03 mmol/L, respectively, with trans fatty acids reducing HDL by
0.02 mmol/L. In addition, individual SFA is known to exert differential effects on
serum HDL-C, so that replacing 5 % energy as carbohydrate with lauric, myristic,
palmitic and stearic, increases HDL-C by 0.13, 0.09, 0.05 and <0.01 mmol/L,
respectively. These associations between dietary fatty acids and serum HDL-C are
statistically robust and have been used to formulate dietary guidelines. However,
because they rely heavily upon data from measures of dietary intake, as estimated
from dietary recall, food frequency questionnaires or diet diaries, this can limit their
value in predicting the biological effects of complex foods on HDL (Astrup
et al. 2011). In other words, foods are not single nutrients, but complex mixtures
of nutrients within a food matrix, all of which interact together to produce a
biological effect. Because a food is rich in one particular fatty acid, it does not
mean that consumption of this food will result in an effect on HDL that is typical of
that fatty acid.
1.2 Dietary MUFA
Interest in the potential health benefits of dietary MUFA originated from the use of
olive oil in the Mediterranean diet. Whilst substitution of SFA with MUFA is less
effective in lowering LDL cholesterol than n-6 PUFA, there is evidence to suggest
that this substitution may be more effective in preventing the decrease in HDL-C
that accompanies the removal of SFA (Schwingshackl and Hoffmann 2012). This
finding is supported by data to show that MUFA is relatively less effective in
stimulating cholesteryl ester transfer protein (CETP), and thus the remodelling and
increased clearance of HDL from serum, than either SFA or n-6 PUFA (Groener
et al. 1991; Lagrost et al. 1999). This finding is in accord with data from a recent
study which concluded that dietary MUFA reduced the catabolic rate of the
principal apolipoprotein (apo) in HDL, apo A-I (Labonte et al. 2013).
1.3 n-3 Polyunsaturated Fatty Acids
The principal essential fatty acid of the n-3 series, α-linolenic acid (18:2) is the most
abundant fatty acid on earth, but is consumed in significantly less quantity by
humans than linoleic acid (18:2 n-6) (National Diet and Nutrition Survey. Depart-
ment of Health 2011). When fed in physiologically relevant amounts, α-linolenic
acid has been shown to be equivalent to linoleic acid as a substitute for SFA in
lowering LDL cholesterol (Harris 1997). However, even though a recent meta-
analysis indicated a benefit of α-linolenic acid intake on CVD risk (Pan et al. 2012),
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human interventions with α-linolenic acid-enriched diets have shown variable
effects on serum HDL-C (Harper et al. 2006; Goyens and Mensink 2006; Kaul
et al. 2008; Griffin et al. 2006). The longer-chain derivatives of α-linolenic acid,
chiefly eicosapentaenoic and docosahexaenoic acids (EPA, DHA), which in
humans are mainly obtained directly from oily fish, exert only a moderate elevating
effect on HDL-C (Harris 1989). This is perhaps surprising given the potent
TAG-lowering effect of these long-chain fatty acids.
1.4 Carbohydrate and Extrinsic Sugars
The replacement of dietary fat with carbohydrate in low-fat, high-carbohydrate
diets has long been associated with a reduction in serum HDL-C that may be linked
to the carbohydrate-induced increase in TAG (Katan et al. 1997). The latter is
known to promote lipid exchanges between HDL- and TAG-rich lipoproteins that
remodel HDL into smaller and denser particles with an increased catabolic rate and
thus reduced residence time in serum. Adverse effects of carbohydrate on HDL-C in
the longer term may also be mediated through increased body weight and the
accumulation of body fat (Stanhope et al. 2013). Whilst the reduction in HDL-C
has been attributed to diets with a high glycaemic index (Frost et al. 1999), there is
now little doubt that the extrinsic sugars, sucrose and fructose make a major
contribution to this effect (Lustig 2010). The findings of a recent meta-analysis
which concluded that a very high intake of fructose (>100 g/d) increases serum
LDL cholesterol, but has no significant effects on HDL-C, are somewhat surprising
in both respects (Zhang et al. 2013) and in contrast to the outcome of dietary
interventions with beverages sweetened with fructose. One example of the latter
showed marked increases in cardiometabolic risk factors, including significant
reductions in serum HDL-C, relative to glucose-sweetened beverages (Stanhope
et al. 2009). A vital question to be answered is whether populations are consuming
amounts of extrinsic sugars which are sufficient to elicit these adverse changes in
HDL in the long term. Dietary intakes in the United Kingdom (National Diet and
Nutrition Survey. Department of Health 2011) indicate that the upper 2.5th percen-
tile of the population may be approaching intakes of extrinsic sugars which have the
potential to induce adverse effects on metabolism and increase body weight. The
overconsumption of sweetened beverages in adolescents is of particular concern in
promoting premature obesity and lowering of HDL-C, as shown in a recent
Australian study (Ambrosini et al. 2013).
1.5 Effects of Dietary Fatty Acids and Cholesterol on HDL
Function
HDL-C is a surrogate marker of HDL particle size and number and may convey
little or no information about the anti-atherosclerotic properties of HDL in the
process of reverse cholesterol. There is evidence to suggest that paradoxical
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increase in HDL-C induced by dietary SFA and cholesterol in mice (Escola-Gil
et al. 2011) and in egg-fed humans (Andersen et al. 2013) results in a beneficial
increase in cholesterol efflux capacity. Beneficial effects of dietary fatty acids on
cholesterol efflux capacity have also been described for EPA and DHA supplemen-
tation in hamsters (Kasbi Chadli et al. 2013) and MUFA-rich extra-virgin olive oil
consumption in humans (Helal et al. 2013). Conversely, several intervention studies
in humans showed no effect on cholesterol efflux capacity of replacing of SFA with
either PUFA (Kralova Lesna et al. 2008) or carbohydrate (De Vries et al. 2005), or
differences between diets enriched with trans fatty acids (8.3 % energy), SFA
(13.2 % energy) and PUFA (14.6 %) elicited by either total plasma HDL or HDL
subfractions (Buonacorso et al. 2007).
In conclusion, evidence from meta-analyses to support the relative effects of
dietary fatty acids on HDL-C may be statistically incontrovertible, but they do not
necessarily translate directly to the effects of complex foods and diets on HDL-C
and CVD risk. Reduction in HDL-C induced by the overconsumption of dietary
extrinsic sugars in sugar-sweetened beverages may have major implications for
cardiometabolic health, especially in adolescents. Finally, evidence for the effects
of dietary components on the anti-atherogenic, functional properties of HDL is
inconclusive and warrants further study.
2 Weight Loss
Obesity, defined as an excess of body fat, is a major health problem in Western
societies (Tchernof and Despres 2013; Bays et al. 2013). Excess body fat is also an
independent risk factor for CVD (Tchernof and Despres 2013). Excessive adipose
tissue accumulation, but more importantly its distribution in the body, particularly
visceral obesity, has been identified as a main correlate of cardiometabolic
disorders including not only alterations in glucose tolerance and insulin sensitivity
but also in blood lipids, including HDL-C.
2.1 Impact of Adiposity on HDL Concentration and Function
Abnormally low plasma HDL-C concentrations accompany hypertriacylgly-
cerolaemia and are a common trait in many obese subjects that contributes to the
development of atherosclerosis (Bays et al. 2013; Tchernof and Despres 2013). In
obesity, the low plasma HDL-C concentration has been mainly attributed to
increased HDL clearance, in part, due to enhanced uptake of HDL by adipocytes
(Wang and Peng 2011; Rashid and Genest 2007). Plasma concentrations of larger
HDL particles are decreased in patients with high cardiovascular risk (Pirillo
et al. 2013) and, similarly, appear to be low in overweight and obese subjects
(Tian et al. 2006, 2011). Moreover, a switch towards a higher proportion of smaller
HDL particles in relation to larger HDL has been reported in the plasma of obese
subjects with ectopic fat and dysfunctional adipose tissue (Tchernof and Despres
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2013). Obesity is commonly associated with increased oxidative stress (Wang and
Peng 2011), and, in this context, there may be impairment of HDL functions,
including reverse cholesterol transport and protection against lipoprotein oxidation.
In this regard, the ability of HDL to mediate cholesterol efflux from cells, which is
considered the first step of reverse cholesterol transport (RCT) (Escola-Gil
et al. 2009), is reduced in the obese (Sasahara et al. 1998; Vazquez et al. 2012).
In addition, although the protection against LDL oxidation conferred by HDL has
not been assessed to date, the antioxidant action of apoA-I has been reported to be
attenuated in scenarios of increased oxidative stress (Kontush and Chapman 2010),
such as that present in obesity (Wang and Peng 2011). Other HDL-associated
proteins such as paraoxonase 1 (PON1) and lipoprotein-associated phospholipase
A2 (Lp-PLA2), which are also main contributors to the antioxidant properties of
HDL (Kontush and Chapman 2010), have been found to be altered in obesity (Seres
et al. 2010; da Silva et al. 2013).
2.2 Effect of Weight-Loss Therapies on HDL Concentration
and Function
Weight loss has been widely thought to be an effective means of achieving a
substantial reduction in cardiometabolic risk (Vest et al. 2012). Obesity-associated
metabolic disorders can, in theory, be treated by lifestyle modifications including
reduced energy intake and/or increased regular, moderate physical activity (Sacks
et al. 2009; Bays et al. 2013). A further strategy to achieve excess weight loss in
severely obese patients is bariatric surgery (Bays et al. 2013). In particular, the
Roux-en-Y gastric bypass (RYGBP) has been reported to induce a sustained weight
reduction without relapse in morbidly obese patients. In contrast, the metabolic
results of lifestyle interventions are variable and insufficient to achieve sustained
weight loss (Vest et al. 2012; Bays et al. 2013), whilst surgery has been shown to
stably improve the lipid profile in most randomised, prospective trials (Bays
et al. 2013; Vest et al. 2012). However, in both approaches, only modest effects
on plasma HDL-C concentrations were reported in most recent systematic reviews
and meta-analyses of stabilised weight-loss clinical trials which examined the
effects of different dietary (Bays et al. 2013; Chapman et al. 2011; Dattilo and
Kris-Etherton 1992; Hu et al. 2012; Sacks et al. 2009; Schwingshackl and
Hoffmann 2013; Singh et al. 2007; Poobalan et al. 2004) or bariatric surgery
programmes (Bays et al. 2013; Vest et al. 2012; Poobalan et al. 2004). There are
few reports directly assessing the effect of weight reduction on HDL remodelling
and its relationship, if any, with its anti-atherogenic properties. In this regard, recent
studies showed that weight loss exerts beneficial changes in HDL subpopulations in
the obese (Aron-Wisnewsky et al. 2011; Asztalos et al. 2010), leading to a switch
towards predominantly larger HDL particles and increased circulating plasma HDL
mass despite no significant impact on plasma HDL-C concentrations. Interestingly,
in one of these studies, an elevation in HDL mass was strongly associated with an
increased capacity of sera from postoperative patients to mediate cholesterol efflux
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via adenosine triphosphate-binding cassette transporter (ABC) G1 and scavenger
receptor class-BI (SR-BI) pathways, relative to baseline values (Aron-Wisnewsky
et al. 2011), thus suggesting that the removal of excess cholesterol from cells by
HDL particles might be enhanced after surgery. Excess weight loss also improves
oxidative stress (Uzun et al. 2004; Gletsu-Miller et al. 2009; Rector et al. 2007).
However, whilst the impact of weight loss on HDL’s antioxidant properties in
severely obese patients undergoing bariatric surgery has been reported in observa-
tional studies, it has not yet been examined in detail (Gletsu-Miller et al. 2009). For
instance, increased PON1 activity levels have been found in serum of patients
undergoing gastric surgery (Uzun et al. 2004), whereas the Lp-PLA2 mass concen-
tration did not change in another study (Hanusch-Enserer et al. 2009). Given that
the distribution of Lp-PLA2 activity between serum lipoproteins is still uncertain,
and evidence to suggest that Lp-PLA2 may be anti-atherogenic when associated
with HDL (Kontush and Chapman 2010), it is reasonable to speculate that the
increase in plasma concentration of larger HDL particles following weight loss
might lead to a proportional increase in anti-atherogenic HDL-associated Lp-PLA2.
Taken together, HDL changes may, in part, account for the significant improve-
ment in the cardiovascular risk observed in obese patients after weight reduction.
Thus, in summary, weight loss has long-term beneficial effects on plasma lipids in
the obese. Regarding the plasma concentration of HDL-C, the impact of lifestyle
interventions appears to be variable and modest in response to different weight-loss
treatments. However, data on the effect of weight-reducing lifestyle interventions
on the functional properties of HDL are scant. Bariatric surgery is becoming a
frequent approach for reducing adiposity and improving the lipid profile in the
severely obese. The excess weight loss following intervention may provide an
interesting scenario for assessing the potential favourable changes in HDL
remodelling and functionality.
3 Effects of Regular Aerobic Exercise
Sedentary behaviour is a major health problem that is associated with increased
cardiometabolic risk. Regular aerobic physical activity results in improved exercise
performance which depends on an increased ability to utilise oxygen to derive
energy for work. These effects usually require exercise intensities ranging from
40 to 85 % of maximal oxygen consumption (VO2 max) or heart rate reserve, with
higher exercise intensities being necessary for higher levels of initial fitness, and
vice versa (Chapman et al. 2011).
3.1 Effects of Exercise on HDL
Regular aerobic physical activity has a positive effect on many of the established
risk factors for CVD by causing a long-lasting reduction in TAGs by up to 20 % and
increasing HDL-C by up to 10 %. It also increases the size of LDL and HDL
particles. All these changes are considered potentially protective against
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atherosclerosis (Kraus et al. 2002; Tall 2002). Given the close interrelation between
plasma TAG-rich particles and HDL, changes in HDL-C after regular aerobic
exercise are probably dependent on an increased HDL synthesis induced by raised
TAG lipolysis (Tall 2002; Olchawa et al. 2004) and, perhaps, also on a reduced
HDL catabolism secondary to decreased hepatic lipase (HL) activity (Bergeron
et al. 2001).
The effect of physical activity on TAG levels varies depending on baseline
TAGs and exercise characteristics such as intensity, caloric expenditure and dura-
tion (Chapman et al. 2011; Miller et al. 2011; Kraus et al. 2002; Kodama
et al. 2007). The reduction in plasma TAGs of 20 % induced by daily exercise
was similar to that obtained by caloric restriction in nonobese subjects (Fontana
et al. 2007). Daily exercise blocked, at least in the short term, the increase in TAGs
induced by a high-carbohydrate diet in healthy postmenopausal women (Koutsari
et al. 2001). Even with a variable adherence to diet, exercise did have a significant
effect on plasma TAG and HDL-C levels (Huffman et al. 2012). In healthy,
non-smoking men, the increase in HDL-C was dependent on exercise intensity
(for instance, miles run per week) (Kokkinos et al. 1995; Tambalis et al. 2009;
Duncan et al. 2005), thus suggesting a dose–response relationship. Between 1,200
and 2,200 Kcal of energy expenditure per week (15–20 miles/week of brisk walking
or jogging) has been estimated to be the threshold for obtaining a significant change
in plasma TAGs and HDL-C (Durstine et al. 2002). The TAG decrease was greater
in individuals with fasting TAGs >1.69 mmol/L than in those with TAGs
<1.69 mmol/L (Couillard et al. 2001). HDL-C increased, particularly in men
with TAGs >1.69 mmol/L and low HDL-C, compared with those with low
HDL-C and TAGs <1.69 mmol/L, and was associated with a reduction in abdomi-
nal adipose tissue (Couillard et al. 2001). This improvement may have been
associated with decreased insulin resistance, adiposity and TAG levels, at least in
part, through increased fatty acid oxidation by the muscle under the control of Rev-
erb-alpha (Tall 2002; Woldt et al. 2013). Whilst data regarding the changes in HDL
functionality induced by regular aerobic training are to date scant and inconsistent,
there is evidence to implicate beneficial changes in some functions of HDL (Iborra
et al. 2008; Kazeminasab et al. 2013; Meissner et al. 2010, 2011).
3.2 Effects of Exercise on Prevention and Treatment
of Cardiometabolic Risk
Obviously, exercise exerts many different effects at a molecular level, rendering it
very difficult to attribute the final effects on disease prevention or treatment to one
effect, including HDL-C.
Several prospective cohort trials have shown a reduction in the risk of type
2 diabetes in individuals participating in physical activity of moderate intensity
compared with being sedentary (Wing 2010; Uusitupa et al. 2009). This difference
was also found in people who walked regularly (typically >2.5 h of brisk walking)
(reviewed by Jeon et al. 2007).
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Regular aerobic exercise is widely considered an important tool for primary and
secondary cardiovascular prevention since it is thought to reduce the risk of fatal
and nonfatal events in the general population (Chapman et al. 2011; Heran
et al. 2011). Although the volume of moderate-intensity physical activity able to
provide a reduction in cardiovascular mortality was initially considered to range
from 2.5 to 5 h/week, similar results appear to be obtainable with 1–1.5 h/week of
vigorous-intensity or a combination of vigorous- and moderate-intensity exercises
(Wen et al. 2011; Sattelmair et al. 2011). However, a systematic review of exercise-
based rehabilitation found a decrease in total and cardiovascular mortality but no
difference in the number of new myocardial infarctions (Heran et al. 2011). Further,
the Look AHEAD Trial which had, as a goal, to achieve and maintain a weight loss
of at least 7 % by both reducing caloric intake and increasing physical activity in
type 2 diabetic patients found no reduction in cardiovascular events in a 10-year
follow-up (Wing et al. 2013). Similar negative results were obtained by the Finnish
Diabetes Prevention Study after a 10-year lifestyle intervention (diet + exercise) in
middle-aged, overweight people with impaired glucose tolerance (Uusitupa
et al. 2009). To interpret these discrepant results, one has to consider differences
in patient disease (type 2 diabetes versus established coronary artery disease) versus
the general population, follow-up time and patient intervention type(s) (Sattelmair
et al. 2011; Wen et al. 2011; Heran et al. 2011; Uusitupa et al. 2009).
Exercise improved the components of the metabolic syndrome in affected
patients (Pattyn et al. 2013). In patients with established type 2 diabetes mellitus
included in the Look AHEAD Trial, increased physical activity had beneficial
effects on glycaemic control and cardiovascular risk factors, including HDL-C
and TAGs (Wing 2010). However, in other studies, aerobic and/or resistance
training was shown to improve glycaemic control, but did not change HDL-C or
TAGs in adults with type 2 diabetes (Sigal et al. 2007). There were major
differences in the number of patients and follow-up time between studies that
should be considered when interpreting these different results (Wing 2010; Sigal
et al. 2007). Furthermore, one study included a hypo-caloric diet together with
exercise (Wing 2010), whereas the other only included exercise (Sigal et al. 2007).
In summary, there appears to be a consensus that regular aerobic exercise raises
HDL-C in a way closely related to plasma TAG reduction. Regular aerobic exercise
may prevent type 2 diabetes and CVD, probably with more intensity in primary than
in secondary prevention. In particular, aerobic exercise does not seem to prevent
CVD in patients with established type 2 diabetes. The role of exercise-induced
changes in HDL in these outcomes is largely unknown.
4 Smoking Cessation
Smoking is a well-documented risk factor for CVD that is amenable to intervention.
A potential mechanism for the atherogenic effect of cigarette smoke is via plasma
HDL. Most research to date has looked at smoking effects on HDL-C concentration
rather than HDL structure or function. One issue that is particularly difficult to
address in observational smoking research is the presence of confounding lifestyle
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behaviours that may cluster with smoking behaviour (such as low physical activity,
poor diet and increased alcohol consumption). Thus, comparison of the properties
of HDL isolated from smokers and non-smokers does not allow direct causal
relationships to be determined, and there is a need for more direct experimental
approaches to dissect the biological effects of smoking and to identify specific
mediating factors (i.e. the combustible products of tobacco such as nicotine, carbon
monoxide and other gaseous products and free radicals). To further complicate the
issue, smoking has effects on TAG metabolism, via increased sympathetic drive,
insulin resistance or both, leading to increased plasma TAG concentrations and
consequent remodelling effects of plasma HDL resulting in higher plasma turnover
[reviewed in Freeman and Packard (1995)].
4.1 Smoking and HDL-C Concentration
Ameta-analysis carried out almost 25 years ago indicated that smoking has a strong
independent effect on plasma HDL-C levels with smokers having on average 6 %
lower HDL-C concentrations compared to non-smokers (Craig et al. 1989). A more
recent meta-analysis, which compared within individual differences before and
after stopping smoking, indicated that the absolute HDL-C concentration difference
was between 0.06 and 0.11 mmol/L (Forey et al. 2013). There also appears to be a
larger smoking effect in women than men (Freeman and Packard 1995). HDL-C
concentrations rise after stopping smoking and fall on restarting, and the magnitude
of the effect on HDL-C is related to the number of cigarettes smoked (Fortmann
et al. 1986; Moffatt et al. 1995; Stubbe et al. 1982; Tuomilehto et al. 1986). There
are no long-lasting effects of smoking on HDL-C concentration after cessation
(Forey et al. 2013), and there is no association between number of years stopped
and plasma HDL-C (Wilson et al. 1983). Passive smoking is also associated with
lower plasma HDL (Moffatt et al. 1995; Neufeld et al. 1997), and a reduction in
HDL-C has been observed acutely only 6 h after exposure to environmental tobacco
smoke (Moffatt et al. 2004). The reduction in plasma HDL-C levels appears to be
limited to a 0.15 mmol/L reduction in the larger HDL2 particles, independent of
confounders, as determined by analytical ultracentrifugation (Freeman et al. 1993).
This has been confirmed by others (Moriguchi et al. 1991; Shennan et al. 1985;
Moffatt et al. 2004), although one study attributed the acute effects of smoking to
the smaller HDL3 fraction (Gnasso et al. 1984). Plasma apoA-I levels are also 6 %
lower in smokers (Craig et al. 1989), and in some studies apoA-II has also been
shown to be reduced in smokers (Berg et al. 1979; Haffner et al. 1985) and
ex-smokers (Richard et al. 1997).
4.2 Potential Mechanisms for the Smoking-Related
Reduction in HDL-C
Because of the intrinsic link between plasma TAG and HDL metabolism,
demonstrated by their negative association in populations, and the biological effects
of smoking on plasma TAG metabolism (Freeman and Packard 1995), it is likely
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that changes in plasma HDL-C concentration could be an indirect effect of
smoking-related increases in plasma TAG concentration. Indeed, much of the effect
of smoking on plasma HDL is lost after statistical correction for changes in plasma
TAGs (Freeman et al. 1993; Phillips et al. 1981). Cigarette smoking affects the
activities of plasma enzymes involved in regulating HDL size and turnover:
lecithin–cholesterol acyltransferase (LCAT) (Freeman et al. 1998; Haffner
et al. 1985) and lipoprotein lipase (LPL) (Freeman et al. 1998; Elkeles
et al. 1983) activities are reduced, whilst HL (Moriguchi et al. 1991) and CETP
(Dullaart et al. 1994) activities are increased. These changes result in a shift in the
size distribution of HDL into smaller particles which have increased clearance from
the plasma compartment (Brinton et al. 1994). However, there is a residual effect of
smoking after correction for changes in plasma TAG, suggesting TAG-independent
effects of smoking on plasma HDL concentration also exist. These
TAG-independent effects appear to be more important in men than women (Free-
man et al. 1993).
There is evidence for structural/compositional changes in HDL brought about by
smoking. Ex vivo experiments, in which human plasma was acutely exposed to
cigarette smoke, resulted in cross-linking of apoA-I and apoA-II (McCall
et al. 1994) that may impair activation of LCAT. Similarly, chemically cross-
linked HDL has an increased clearance in rodents (Senault et al. 1990). Smoking
is associated with a reduction in the HDL content of Lp-PLA2, an enzyme thought
to play an anti-atherogenic role in HDL (Tselepis et al. 2009). Early studies showed
that chronic inhalation of cigarette smoke in pigeons inhibits liver HDL uptake
(Mulligan et al. 1983). Recent data have shown that a by-product of cigarette
smoking, benzo(a)pyrene, inhibited apoA-I synthesis in HepG2 cells, via activation
of the aryl hydrocarbon nuclear steroid receptor, whilst nicotine had no effect
(Naem et al. 2012). Modelling of the monocyte transcriptome in smokers compared
to non-smokers identified SLC39A8 to be on a causal pathway between smoking
and plaque formation (Verdugo et al. 2013). This gene is known to be associated
with the cellular uptake of cadmium from tobacco and was negatively associated
with HDL cholesterol levels in this study.
There are very few studies on the effects of smoking on HDL function. HDL
isolated from smokers showed reduced ability to induce cholesterol efflux from
macrophages, possibly via apoA-I-mediated effects (Kralova Lesna et al. 2012). Ex
vivo cigarette smoke treated HDL, which resulted in an increased conjugated diene
and denatured apoA-I content, reduced the efflux capacity of HDL to a level similar
to that of copper-oxidised HDL (Ueyama et al. 1998). Co-incubation with superox-
ide dismutase prevented approximately half of the impairment and reduced the
level of conjugated dienes, but not the apoA-I denaturation. There is also some
evidence that plasma thiocyanates found in high levels in smokers could cause HDL
oxidation and reduced apoA-I cholesterol efflux ability (Hadfield et al. 2013).
Smoking is associated with reduced activity and concentration of PON1, an
HDL-associated antioxidant enzyme, effects which are reversed after smoking
cessation (James et al. 2000). The mechanistic data for the effects of smoking on
HDL function are far from comprehensive and merit further investigation.
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4.3 Smoking Cessation Intervention to Increase Plasma HDL
Concentration
The majority of smoking cessation studies are small, and most, but not all, have
been shown to result in a rise in HDL concentration. A meta-analysis of 27 studies
incorporating over 6,000 subjects indicated that HDL-C increased by 0.10 mmol/L
after smoking cessation, whilst plasma total cholesterol, LDL-C and TAG did not
change (Maeda et al. 2003).
A number of lifestyle changes may also occur when smokers cease smoking, and
at least one study has shown that the rise in HDL after smoking cessation is not
independent of the change in diet (Quensel et al. 1989b). However, refuting this, a
recent large randomised, double-blind controlled trial was carried out in over 1,500
smokers smoking an average of 21 cigarettes per day (Gepner et al. 2011). Patients
were randomised to one of six treatments: nicotine lozenge, nicotine patch,
sustained-release bupropion, nicotine patch plus nicotine lozenge, sustained-release
bupropion plus nicotine lozenge, or placebo. Of the 923 participants who returned
after 1 year intervention, 36 % who had stopped smoking showed a significantly
greater rise in HDL-C than those who did not, despite gaining an average of 4 kg
more weight than those who continued to smoke. The effects of smoking cessation
in this study were particularly evident in women.
Transdermal nicotine replacement therapy is a commonly used approach to
support smoking cessation. A small study was carried out to compare the effects
of transdermal nicotine patches, used as part of a smoking cessation intervention, on
plasma HDL-C levels (Moffatt et al. 2000). Subjects who used transdermal nicotine
patches over 35 days showed no improvement in HDL-C concentration. However,
if the use of patches was then stopped, HDL-C concentrations rose to normal,
non-smoking levels over the next 42 days. Others have observed contrasting effects
in a larger study where smoking cessation, accompanied by the use of higher-dose
nicotine transdermal patches, resulted in an immediate increase in HDL, whereas in
contrast, low-dose nicotine did not (Allen et al. 1994). These latter findings are
somewhat contradictory to data indicating that nicotine administration to
non-smokers, via chewing gum, does not affect HDL-C levels (Quensel
et al. 1989a). The potential effects of nicotine patches during smoking cessation
on plasma HDL have yet to be clarified.
In summary, smoking leads to a reduction in plasma HDL-C, HDL2-C, apo A-I
and probably apoA-II concentrations. The effects of smoking on HDL are dose
dependent and reversed upon smoking cessation. Much of the effect of smoking
may be TAG dependent where increased plasma TAG concentration leads to
remodelling of HDL to a smaller particle size which is more rapidly cleared from
the circulation. TAG-independent effects have not yet been thoroughly investigated
but include modification of apoA-I, reductions in HDL antioxidant enzyme activity
and reduced ability of HDL to promote cholesterol efflux. The effect of nicotine
aids, used to support smoking cessation interventions, on HDL-C concentration and
function is unclear.
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5 Effects of Alcohol on HDL and Cardiovascular Risk
Multiple studies have established a known J-shaped relationship between alcohol
intake and cardiovascular risk including coronary heart disease and ischaemic
stroke (Krenz and Korthuis 2012). The term ‘drink’ is imprecise; however, the
amount of alcohol in one drink is similar for wine, spirits or beer. Thus, a 100 ml
glass of table wine at 13 % alcohol, 35 ml of distilled spirits at 40 % alcohol and
300 ml of beer at 5 % alcohol all contain around 10–12 g of pure ethyl alcohol. The
general consensus is that men consuming two standard alcoholic drinks per day and
women consuming half that intake appear to have a lower cardiovascular event rate
than persons abstaining from alcohol (Krenz and Korthuis 2012). Estimates of the
risk reduction associated with moderate alcohol intake drinkers compared with
those abstaining from alcohol range from 25 to 30 % (Krenz and Korthuis 2012).
5.1 Alcohol Intake and HDL-C
Several plausible mechanisms have been proposed to explain the positive moderate
alcohol intake-mediated effects on CVDs: reduced thrombogenic and coagulation
factors (platelet aggregation and fibrinogen levels), low plasma concentrations of
inflammation markers (C-reactive protein, interleukin-6 and adiponectin), lowered
blood pressure, increased insulin sensitivity and lipoprotein profile via a lowering
of LDL-C and increase in HDL-C (Klatsky 2010). However, this alcohol–CVD
relationship is nonlinear, and excessive alcohol consumption has adverse effects on
hypertension and other pro-inflammatory factors, despite increasing HDL-C
(Foerster et al. 2009).
Some reports have suggested that wine carries a lower risk of mortality than beer
or spirits and that this may be related to the ability of nonalcoholic phenolic
compounds to inhibit LDL oxidation and its pro-inflammatory effects (Frankel
et al. 1993; Gronbaek et al. 2000; Klatsky et al. 2003). However, other studies
have failed to identify an additional advantage associated with red wine
(Di Castelnuovo et al. 2002; Mukamal et al. 2003), thereby suggesting that ethyl
alcohol is the main factor for the cardioprotective effect.
A recent meta-analysis demonstrated that alcohol exerts favourable effects on
several cardiovascular biomarkers (higher HDL-C, apoA-I and adiponectin levels
and lower fibrinogen levels) which seems to be independent of the alcoholic
beverage type (Brien et al. 2011). This systematic review found that 1–2 drinks
per day increased HDL-C by 0.10 mmol/L (Brien et al. 2011). However, the
contribution of alcohol-induced HDL-C-raising effects to cardiovascular risk
remains largely unknown. Early studies indicated that the atheroprotective effects
were mediated, largely, by the increase in HDL-C, since the addition of HDL-C to
the multivariate model attenuated the inverse association between alcohol intake
and myocardial infarction (Gaziano et al. 1993). Nevertheless, one recent report
describing a large Norwegian cohort with extensive control for confounding factors
showed that HDL-C levels were not on the causal pathway connecting alcohol to
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the lower risk of death from coronary heart disease (Magnus et al. 2011). These
findings raise the question of which specific HDL subpopulation particles are
affected by alcohol intake and their significance for coronary heart disease
protection.
5.2 Effects of Alcohol on HDL Atheroprotective Functions
Studies on the effect of alcohol consumption on HDL particle size are inconsistent.
In some studies, moderate alcohol consumption increased small HDL subfractions,
mainly HDL3 (Haskell et al. 1984; Gardner et al. 2000; Nishiwaki et al. 1994), and
lipid-poor preβ-HDL particles (Beulens et al. 2004). These effects on HDL size
could be related to the ability of alcohol to stimulate LPL activity (Nishiwaki
et al. 1994). However, other studies on moderate drinkers found increased
concentrations of both HDL2 and HDL3 (Gaziano et al. 1993; Clevidence
et al. 1995; De Oliveira et al. 2000), and human kinetic studies demonstrated that
moderate alcohol consumption resulted in dose-dependent increases in HDL-C,
apoA-I and apoA-II through an increase in the HDL apolipoprotein transport rate,
but without altering their catabolic rate and LPL activity (De Oliveira et al. 2000).
These changes might explain the ability of HDL from moderate alcohol drinkers to
enhance macrophage cholesterol efflux (Beulens et al. 2004). However, cholesterol
efflux was also enhanced in heavy drinkers who usually show larger HDL (Makela
et al. 2008); these changes were associated with decreased CETP activity and
increased phospholipid transfer protein (PLTP) activity (Makela et al. 2008). It
should be noted that these macrophage cholesterol efflux assays only quantified the
first-step RCT pathway without addressing the efficiency of the rest of the RCT
steps or the other HDL cardioprotective functions. Nevertheless, moderate alcohol
intake was not associated with changes in the activities of other HDL remodelling
factors, such as LCAT or CETP (Nishiwaki et al. 1994; Riemens et al. 1997;
Sierksma et al. 2004), and, furthermore, the ability of HDL to deliver cholesterol
into the liver cells seemed to be decreased in both moderate and heavy drinkers
(Rao et al. 2000; Marmillot et al. 2007).
Beyond the RCT pathway, moderate alcohol consumption increased serum
PON1 (van der Gaag et al. 1999; Sierksma et al. 2002; Rao et al. 2003), along
with liver PON1 mRNA levels (Rao et al. 2003), although this effect was not found
in one study with moderate red wine drinkers (Sarandol et al. 2003). In contrast,
heavy alcohol drinking produced the opposite effects (Rao et al. 2003). Further-
more, alcohol promotes the conversion of phosphatidylcholine into phosphatidy-
lethanol, and it was reported that HDL-associated phosphatidylethanol increased
endothelial secretion of the vascular endothelial growth factor (Liisanantti and
Savolainen 2009), which could partly explain the positive effect of alcohol on
angiogenesis induction.
In summary, the inverse relationship between moderate and regular alcohol
intake and cardiovascular risk as well as the ability of alcohol to increase HDL-C
is well documented in the literature. Although some studies reported favourable
HDL and Lifestyle Interventions 583
effects of alcohol on HDL cardioprotective functions, it is unclear how many of the
alcohol-mediated cardioprotective effects were mediated by the HDL increase.
Finally, the American Heart Association recommendation that alcoholic beverage
consumption should be limited to no more than 2 drinks per day for men and 1 drink
per day for women and should be consumed with meals should be taken into
account. Alcohol should not be considered a therapeutic option for cardiovascular
risk reduction (Lichtenstein et al. 2006).
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